Tell Congress to Support the MINI Act
 

Patients with serious and rare diseases need more treatment options—not fewer.

Some of today’s most promising therapies are being developed for conditions like sickle cell disease, certain cancers, muscular dystrophy, hemophilia, and rare genetic disorders. But under current law, similar therapies can be treated differently based on a technical classification—meaning some could face Medicare price negotiation years earlier than others, even when they are intended to treat similarly serious conditions.

For highly specialized therapies—especially those developed for smaller patient populations—shortening the time available to recover the extraordinary costs of research, development, and manufacturing can make some treatments less likely to be pursued at all.

Patients should not lose future treatment options because of a technicality in how a therapy is classified.

The MINI Act would help fix this problem and protect access to future treatments patients and families are counting on.

Take Action

Tell Congress to support the MINI Act.

Send your message now.